AUS
NZ
UK
CA
USA
IND
Opus Genetics, Inc. announced that Chief Executive Officer George Magrath completed the sale of 9,475 common shares on July 23, 2026, through an automatic transaction designed to fulfill tax withholding requirements tied to the vesting and settlement of restricted stock units. The shares were sold at a weighted average price of $2.9473 each. After this transaction, Magrath continues to hold beneficial ownership of 1,731,869 common shares directly.
Key Points
- NASDAQ: IRD
- CEO George Magrath sold 9,475 common shares on July 23, 2026
- Shares sold at a weighted average price of $2.9473, with individual prices ranging from $2.9009 to $3.025 per share
- Sale was automatic and non-discretionary, executed to cover tax withholding obligations from RSU vesting
- Magrath retains direct beneficial ownership of 1,731,869 common shares after the transaction
Automatic Share Sale Executed to Meet Tax Withholding Obligations
George Magrath, Director and CEO of Opus Genetics, Inc., conducted an automatic, non-discretionary sale of shares on July 23, 2026. This transaction was carried out by the company on Magrath's behalf to satisfy tax withholding obligations resulting from the vesting and settlement of restricted stock units (RSUs). Such automatic sales are common among public companies, enabling executives to meet tax liabilities without initiating discretionary sales.
The filing clarifies that this transaction was not a voluntary trade by Magrath but an administrative action by Opus Genetics to address tax consequences of equity compensation vesting. Under securities regulations, these automatic sales differ from discretionary insider trades that reflect personal investment decisions.
Share Sale Pricing and Volume Details
The 9,475 shares were sold in multiple transactions on July 23, 2026, at prices ranging from $2.9009 to $3.025 per share. The weighted average price was $2.9473. The filing commits to providing detailed information on the number of shares sold at each price point if requested by the issuer, shareholders, or the Securities and Exchange Commission staff.
The narrow price range of approximately $0.12 per share indicates the sales occurred within a brief trading period, consistent with the automatic nature of the transaction. This pricing transparency allows investors to understand the valuation at which the CEO’s shares were sold to cover tax liabilities.
Post-Transaction Beneficial Ownership of CEO George Magrath
After the July 23, 2026 sale, George Magrath retains direct beneficial ownership of 1,731,869 common shares of Opus Genetics. This amount reflects his holdings following the automatic disposition of 9,475 shares for tax purposes. The disclosure confirms all shares are held directly by Magrath without indirect ownership structures.
This substantial remaining stake indicates Magrath maintains a significant financial interest in the company despite the tax-related share sale. While the filing does not specify percentage ownership, the CEO’s holdings remain material relative to the company’s overall capitalization.
Restricted Stock Unit Vesting and Equity Compensation Context
The disclosed transaction stems from the vesting and settlement of RSUs awarded to Magrath. RSUs are a standard form of executive equity compensation at public companies. Upon vesting, RSUs convert into common stock, triggering income tax liabilities for the recipient.
To cover these tax obligations, many companies authorize automatic sales of shares sufficient to generate withholding proceeds. This process simplifies tax compliance and avoids the risks and timing challenges executives might face if selling shares independently. The July 23, 2026 transaction aligns with this common administrative practice.
Executive Role and Insider Reporting Compliance
As both Director and CEO, George Magrath is subject to Section 16(a) of the Securities Exchange Act of 1934, which mandates reporting of beneficial ownership changes. Form 4 filings serve as the official disclosure mechanism for insider transactions by officers and directors.
The Form 4 was signed on Magrath’s behalf by Amy Rabourn under power of attorney on July 27, 2026, three business days after the transaction. This timing complies with the SEC’s five-calendar-day filing deadline for insider trades. The use of power of attorney is a common administrative practice at large public companies.
Transparency in Insider Transaction Disclosures
The filing’s detailed pricing disclosure, including the range and weighted average prices, reflects regulatory transparency requirements for insider trades. By noting multiple price points within a narrow range, the report enables investors to assess market conditions during the CEO’s share sale. The company’s commitment to provide further details upon request enhances regulatory and shareholder oversight.
Form 4 disclosures are vital for market participants tracking executive and director trading activities. Although automatic sales for tax withholding differ from discretionary trades, they remain important indicators of insider ownership changes. Transparent reporting allows investors to monitor whether executive holdings are increasing or decreasing over time.
No Indication of Material Adverse Developments
The filing contains no evidence of adverse operational or financial changes at Opus Genetics. The transaction is purely an administrative response to tax withholding obligations from equity compensation vesting. No forward-looking statements, guidance updates, or negative business news accompany this insider transaction report.
Investors should understand that automatic insider share sales for tax purposes do not inherently signal positive or negative views on the company’s future prospects. These sales are triggered mechanically by vesting events and tax requirements rather than executive decisions about stock value. The filing does not provide any insight into management’s sentiment on future stock performance.
Ongoing Regulatory Compliance and Record Maintenance
The Form 4 filing demonstrates Opus Genetics’ adherence to federal securities laws governing insider transaction reporting. The company maintains systems to track and disclose beneficial ownership changes by insiders, making these filings publicly accessible via regulatory databases such as EDGAR.
The notation that Magrath remains subject to Section 16 reporting requirements confirms his continued role as Director, Officer, or both, subject to insider trading rules. Investors can expect ongoing access to Form 4 filings documenting any future transactions by Magrath or other insiders at Opus Genetics.
